Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Prior treatment

• Use, or anticipated use during the course of the study, of a prohibited medication as listed in Section 6.7.1 of the protocol
• Non-compliance with study medication(s) (defined as taking \<75% or \>125% of the study drug provided) during the first 12 weeks of MLS-101-901

Other illness

• In the opinion of the Investigator, any condition that will preclude participation in the study
  • \[Randomized treatment withdrawal substudy only\]

Other

• Women who are pregnant, plan to become pregnant, or are breast-feeding

• Written informed consent signed by the participant, obtained before any study-related assessment is performed
• At least 18 years of age at the time of signing the informed consent form (ICF)
• Completed the EoT or EoS Visit (as applicable) in a lorundrostat study with the option of transitioning to the OLE study, in accordance with the parent study protocol
• Fertile male subjects and female subjects of childbearing potential, and their partners, must agree to use an acceptable method of contraception from study entry to 28 days after the last dose of study drug
• Willing and able to comply with the study instructions and attend all scheduled study visits
  • \[Randomized treatment withdrawal substudy only\]
• Written informed consent to participate in the RTW substudy signed by the participant, obtained before any RTW study-related assessment is performed